

**WEREWOLF THERAPEUTICS, INC.**  
1030 Massachusetts Avenue, Suite 210  
Cambridge, MA 02138

May 18, 2022

**VIA EDGAR**

Securities and Exchange Commission  
Division of Corporation Finance  
100 F Street, N.E.  
Washington, D.C. 20549

Re: Werewolf Therapeutics, Inc.  
Registration Statement on Form S-3  
File No. 333-264844  
Request for Acceleration

Ladies and Gentlemen:

Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Werewolf Therapeutics, Inc. (the "Registrant") hereby requests acceleration of the effective date of its Registration Statement on Form S-3 (File No. 333-264844), so that it may become effective at 4:30 p.m. Eastern time on May 20, 2022, or as soon thereafter as practicable, or at such later time as the Registrant or its counsel may orally request via telephone call to the staff.

Very truly yours,

**WEREWOLF THERAPEUTICS, INC.**

By: /s/ Daniel J. Hicklin  
Name: Daniel J. Hicklin, Ph.D.  
Title: President and Chief Executive Officer

cc: Rosemary G. Reilly  
Stephanie Leopold  
*Wilmer Cutler Pickering Hale and Dorr LLP*